Referenties jicht
1. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003; 349:1647-55.
2. Rutsch F, Terkeltaub R. Parallels between arterial and cartilage calcification:
what understanding artery calcification can teach us about chondrocalcinosis.
Curr Opin Rheumatol 2003; 15:302-10.
3. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts
the immune system to dying cells. Nature 2003; 425:516-21.
4. Doherty M. Calcium pyrophosphate dihydrate crystal-associated arthropathy. In:
Hochberg MC, Silman AJ, Smolen JS, Weinblatt ME, Weisman MH, editors.
Rheumatology. Philadelphia: Mosby, 2003: 1937-50.
5. Hall AP, Barry PE, Dawber TR, McNamara PM. Epidemiology of gout and
hyperuricemia. A long-term population study. Am J Med 1967; 42:27-37.
6. Levinson DJ. Clincal gout and the pathogenesis of hyperuricemia. In: McCarthy
DJ, editor. Arthritis and allied conditions. Philadelphia: Lea & Febiger, 1989:
1645-76.
7. Fam AG. Gout in the elderly. Clinical presentation and treatment. Drugs Aging
1998; 13:229-43.
8. Yu TF, Gutman AB. Principles of current management of primary gout. Am J Med
Sci 1967; 254:893-907.
9. Gutman AB. The past four decades of progress in the knowledge of gout, with an
assessment of the present status. Arthritis Rheum 1973; 16:431-45.
10. Schapira D, Stahl S, Izhak OB, Balbir-Gurman A, Nahir AM. Chronic tophaceous
gouty arthritis mimicking rheumatoid arthritis. Semin Arthritis Rheum 1999;
29:56-63.
11. Talbott JH, Altman RD, Yu TF. Gouty arthritis masquerading as rheumatoid
arthritis or vice versa. Semin Arthritis Rheum 1978; 8:77-114.
12. Fam AG. Alternate urate-lowering drugs and the management of hyperuricemia
in allopurinol-intolerant patients. Intern J Adv Rheumatol 2003; 1:122-30.
13. Kramer HM, Curhan G. The association between gout and nephrolithiasis: the
National Health and Nutrition Examination Survey III, 1988-1994. Am J Kidney
Dis 2002; 40:37-42.
14. Dieppe PA. Investigation and management of gout in the young and the elderly.
Ann Rheum Dis 1991; 50:263-6.
15. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia. Risks and
consequences in the Normative Aging Study. Am J Med 1987; 82:421-6.
16. Gibson T, Rodgers AV, Simmonds HA, Toseland P. Beer drinking and its effect
on uric acid. Br J Rheumatol 1984; 23:203-9.
17. Wortmann RL. Gout and hyperuricemia. Curr Opin Rheumatol 2002; 14:281-6.
18. Jeha S. Tumor lysis syndrome. Semin Hematol 2001; 38:4-8.
19. McLean L. The pathogenesis of gout. In: Hochberg MC, Silman AJ, Smolen JS,
Weinblatt ME, Weisman MH, editors. Rheumatology. Philadelphia: Mosby, 2003:
1903-18.
20. Landis RC, Yagnik DR, Florey O, Philippidis P, Emons V, Mason JC, et al. Safe
disposal of inflammatory monosodium urate monohydrate crystals by
differentiated macrophages. Arthritis Rheum 2002; 46:3026-33.
21. Benzie IF. Evolution of antioxidant defence mechanisms. Eur J Nutr 2000; 39:5361.
22. Rigby AS, Wood PH. Serum uric acid levels and gout: what does this herald for
the population? Clin Exp Rheumatol 1994; 12:395-400.
23. Logan JA, Morrison E, McGill PE. Serum uric acid in acute gout. Ann Rheum Dis
1997; 56:696-7.
24. Watt I, Middlemiss H. The radiology of gout. Review article. Clin Radiol 1975;
26:27-36.
2
25. Pascual E, Tovar J, Ruiz MT. The ordinary light microscope: an appropriate tool
for provisional detection and identification of crystals in synovial fluid. Ann
Rheum Dis 1989; 48:983-5.
26. Galvez J, Saiz E, Linares LF, Climent A, Marras C, Pina MF, et al. Delayed
examination of synovial fluid by ordinary and polarised light microscopy to detect
and identify crystals. Ann Rheum Dis 2002; 61:444-7.
27. Kerolus G, Clayburne G, Schumacher HR, Jr. Is it mandatory to examine
synovial fluids promptly after arthrocentesis? Arthritis Rheum 1989; 32:271-8.
28. O'Reilly S, Doherty M. Missed opportunity following diagnosis of gout. Ann
Rheum Dis 1995; 54:86-7.
29. Emmerson B. Hyperlipidaemia in hyperuricaemia and gout. Ann Rheum Dis
1998; 57:509-10.
30. Schumacher HR, Jr., Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J,
et al. Randomised double blind trial of etoricoxib and indometacin in treatment of
acute gouty arthritis. BMJ 2002; 324:1488-92.
31. Soto O, Hedley-Whyte ET. Case records of the Massachusetts General Hospital.
Weekly clinicopathological exercises. Case 33-2003. A 37-year-old man with a
history of alcohol and drug abuse and sudden onset of leg weakness. N Engl J
Med 2003; 349:1656-63.
32. Schreiner A, Kalager T, Vaula D. Leukocyte migration in different systems. Effect
of colchicin. Kinetics of migration under agarose. Acta Pathol Microbiol Scand [C
] 1980; 88:89-96.
33. Spilberg I, Mandell B, Mehta J, Simchowitz L, Rosenberg D. Mechanism of action
of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979; 64:77580.
34. Ouyang Y, Wang W, Bhuta S, Chang YH. Mechanism of action of colchicine. VI:
Effect of colchicine on generation of leukotriene B4 by human polymorphonuclear
leukocytes. Clin Exp Rheumatol 1989; 7:397-402.
3
35. Levine AM. Challenges in the management of Burkitt's lymphoma. Clin
Lymphoma 2002; 3 Suppl 1:S19-S25.
36. Baeksgaard L, Sorensen JB. Acute tumor lysis syndrome in solid tumors--a case
report and review of the literature. Cancer Chemother Pharmacol 2003; 51:18792.
37. Bosly A, Sonet A, Pinkerton CR, McCowage G, Bron D, Sanz MA, et al.
Rasburicase (recombinant urate oxidase) for the management of hyperuricemia
in patients with cancer: report of an international compassionate use study.
Cancer 2003; 98:1048-54.
38. Ettinger B, Tang A, Citron JT, Livermore B, Williams T. Randomized trial of
allopurinol in the prevention of calcium oxalate calculi. N Engl J Med 1986;
315:1386-9.
39. Fam AG. Difficult gout and new approaches for control of hyperuricemia in the
allopurinol-allergic patient. Curr Rheumatol Rep 2001; 3:29-35.
40. Perez-Ruiz F, Alonso-Ruiz A, Calabozo M, Herrero-Beites A, Garcia-Erauskin G,
Ruiz-Lucea E. Efficacy of allopurinol and benzbromarone for the control of
hyperuricaemia. A pathogenic approach to the treatment of primary chronic gout.
Ann Rheum Dis 1998; 57:545-9.
41. Basin KS, Escalante A, Beardmore TD. Severe pancytopenia in a patient taking
low dose methotrexate and probenecid. J Rheumatol 1991; 18:609-10.
42. Canhao H, Fonseca JE, Leandro MJ, Romeu JC, Pimentao JB, Costa JT, et al.
Cross-sectional study of 50 patients with calcium pyrophosphate dihydrate
crystal arthropathy. Clin Rheumatol 2001; 20:119-22.
43. Muthukumar N, Karuppaswamy U. Tumoral calcium pyrophosphate dihydrate
deposition disease of the ligamentum flavum. Neurosurgery 2003; 53:103-8.
44. Deesomchok U, Tumrasvin T. Clinical pattern of females with crystal-induced
arthritis: gout and pseudogout. J Med Assoc Thai 1989; 72:212-7.
4
45. Resnick D, Williams G, Weisman MH, Slaughter L. Rheumatoid arthritis and
pseudo-rheumatoid arthritis in calcium pyrophosphate dihydrate crystal
deposition disease. Radiology 1981; 140:615-21.
46. Donich AS, Lektrakul N, Liu CC, Theodorou DJ, Kakitsubata Y, Resnick D.
Calcium pyrophosphate dihydrate crystal deposition disease of the wrist:
trapezioscaphoid joint abnormality. J Rheumatol 2000; 27:2628-34.
47. Resnick D, Niwayama G, Goergen TG, Utsinger PD, Shapiro RF, Haselwood
DH, et al. Clinical, radiographic and pathologic abnormalities in calcium
pyrophosphate dihydrate deposition disease (CPPD): pseudogout. Radiology
1977; 122:1-15.
48. Resnick D, Niwayama G, Coutts RD. Subchondral cysts (geodes) in arthritic
disorders: pathologic and radiographic appearance of the hip joint. AJR Am J
Roentgenol 1977; 128:799-806.
49. Resnik CS, Resnick D. Crystal deposition disease. Semin Arthritis Rheum 1983;
12:390-403.
50. Resnick D, Utsinger PD. The wrist arthropathy of "pseudogout" occurring with
and without chondrocalcinosis. Radiology 1974; 113:633-41.
51. Moskowitz RW. Diseases associated with the deposition of calcium
pyrophosphate or hydroxyapatite. In: Kelley WN, Harris ED, Ruddy S, Sledge
CB, editors. Textbook of rheumatology. Philadelphia: Saunders Company, 1989:
1449-67.
52. Timms AE, Sathananthan R, Bradbury L, Athanasou NA, Wordsworth BP, Brown
MA. Genetic testing for haemochromatosis in patients with chondrocalcinosis.
Ann Rheum Dis 2002; 61:745-7.
53. Glass JS, Grahame R. Chondrocalcinosis after parathyroidectomy. Ann Rheum
Dis 1976; 35:521-5.
54. Picher M, Graff RD, Lee GM. Extracellular nucleotide metabolism and signaling
in the pathophysiology of articular cartilage. Arthritis Rheum 2003; 48:2722-36.
5
55. Pendleton A, Johnson MD, Hughes A, Gurley KA, Ho AM, Doherty M, et al.
Mutations in ANKH cause chondrocalcinosis. Am J Hum Genet 2002; 71:933-40.
56. Zitnan D, Sitaj S. Classification of primary articular chondrocalcinosis. Czech
Med 1979; 2:89-103.
57. Alexander GM, Dieppe PA, Doherty M, Scott DG. Pyrophosphate arthropathy: a
study of metabolic associations and laboratory data. Ann Rheum Dis 1982;
41:377-81.
58. Geelhoed GW, Kelly TR. Pseudogout as a clue and complication in primary
hyperparathyroidism. Surgery 1989; 106:1036-41, discussion.
59. Doherty M, Dieppe PA. Acute pseudogout: "crystal shedding" or acute
crystallization? Arthritis Rheum 1981; 24:954-7.
60. Ivorra J, Rosas J, Pascual E. Most calcium pyrophosphate crystals appear as
non-birefringent. Ann Rheum Dis 1999; 58:582-4.
61. Doherty M. Calcium pyrophosphate deposition disease and other crystal
deposition diseases. Curr Opin Rheumatol 1990; 2:789-96.
62. McGill PE, Grange AT, Royston CS. Chondrocalcinosis in primary
hyperparathyroidism. Influence of parathyroid activity and age. Scand J
Rheumatol 1984; 13:56-8.
63. Pritchard MH, Jessop JD. Chondrocalcinosis in primary hyperparathyroidism.
Influence of age, metabolic bone disease, and parathyroidectomy. Ann Rheum
Dis 1977; 36:146-51.
64. Rynes RI, Merzig EG. Calcium pyrophosphate crystal deposition disease and
hyperparathyroidism: a controlled, prospective study. J Rheumatol 1978; 5:4608.
65. Yashiro T, Okamoto T, Tanaka R, Ito K, Hara H, Yamashita T, et al. Prevalence
of chondrocalcinosis in patients with primary hyperparathyroidism in Japan.
Endocrinol Jpn 1991; 38:457-64.
6
66. Louthrenoo W, Sukitawut W. Calcium pyrophosphate dihydrate crystal
deposition: a clinical and laboratory analysis of 91 Thai patients. J Med Assoc
Thai 1999; 82:569-76.
67. Roane DW, Harris MD, Carpenter MT, Finger DR, Jarek MJ, Alloway JA, et al.
Prospective use of intramuscular triamcinolone acetonide in pseudogout. J
Rheumatol 1997; 24:1168-70.
68. Jahangier ZN, Moolenburgh JD, Jacobs JW, Serdijn H, Bijlsma JW. The effect of
radiation synovectomy in patients with persistent arthritis: a prospective study.
Clin Exp Rheumatol 2001; 19:417-24.
69. Bahous I. [Periarthritis calcarea]. Schweiz Med Wochenschr 1982; 112:897-904.
70. Contreras M, Nolla JM, Mateo L, Rozadilla A. [Pseudopodagra caused by
hydroxyapatite. Report of 3 cases]. Rev Clin Esp 1993; 192:173-4.
71. Schumacher HR, Smolyo AP, Tse RL, Maurer K. Arthritis associated with apatite
crystals. Ann Intern Med 1977; 87:411-6.
72. Gibilisco PA, Schumacher HR, Jr., Hollander JL, Soper KA. Synovial fluid
crystals in osteoarthritis. Arthritis Rheum 1985; 28:511-5.
73. Dieppe PA, Crocker PR, Corke CF, Doyle DV, Huskisson EC, Willoughby DA.
Synovial fluid crystals. Q J Med 1979; 48:533-53.
74. Dieppe PA, Crocker P, Huskisson EC, Willoughby DA. Apatite deposition
disease. A new arthropathy. Lancet 1976; 1:266-9.
75. Riley GP, Harrall RL, Constant CR, Cawston TE, Hazleman BL. Prevalence and
possible pathological significance of calcium phosphate salt accumulation in
tendon matrix degeneration. Ann Rheum Dis 1996; 55:109-15.
76. Bardin T, Bucki B, Lansaman J, Bravo EO, Ryckewaert A, Dryll A. [Alizarin red
staining of articular fluids. Comparison of the results with electron microscopy
and clinical data]. Rev Rhum Mal Osteoartic 1987; 54:149-54.
7
77. Eggelmeijer F, Dijkmans BA, Macfarlane JD, Cats A. Alizarin red S staining of
synovial fluid in inflammatory joint disorders. Clin Exp Rheumatol 1991; 9:11-6.
78. Maldonado I, Prasad V, Reginato AJ. Oxalate crystal deposition disease. Curr
Rheumatol Rep 2002; 4:257-64.
79. Reginato AJ, Ferreiro Seoane JL, Barbazan AC, Mitja PJ, Vidal ML, Pascual TR,
et al. Arthropathy and cutaneous calcinosis in hemodialysis oxalosis. Arthritis
Rheum 1986; 29:1387-96.
80. Bedani PL, Orzincolo C, Storari A, Perini L, Soffritti S, Gilli P. Clinical and
radiological features of bone disease in long-term (15 or more years)
hemodialysis patients. Int J Artif Organs 1993; 16:704-10.
81. Coe FL, Parks JH, Asplin JR. The pathogenesis and treatment of kidney stones.
N Engl J Med 1992; 327:1141-52.
82. Jacobs JW, Bijlsma JW. [Diagnostic image (57). Tenosynovial swelling with
cholesterol crystals in rheumatoid arthritis]. Ned Tijdschr Geneeskd 2001;
145:1886.
83. Balint PV, Kane D, Sturrock RD. Case number 26: massive cholesterol crystal
deposition: unusual location in rheumatoid arthritis. Ann Rheum Dis 2003;
62:512.
84. Gordon C, Swan A, Dieppe P. Detection of crystals in synovial fluids by light
microscopy: sensitivity and reliability. Ann Rheum Dis 1989; 48:737-42.
8